CN103209992A - 具有减少的细胞摄取的因子viii变体 - Google Patents

具有减少的细胞摄取的因子viii变体 Download PDF

Info

Publication number
CN103209992A
CN103209992A CN2011800549583A CN201180054958A CN103209992A CN 103209992 A CN103209992 A CN 103209992A CN 2011800549583 A CN2011800549583 A CN 2011800549583A CN 201180054958 A CN201180054958 A CN 201180054958A CN 103209992 A CN103209992 A CN 103209992A
Authority
CN
China
Prior art keywords
fviii
variant
cells
binding
lrp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800549583A
Other languages
English (en)
Chinese (zh)
Inventor
H.梅姆斯
A.B.梅耶斯
K.默滕斯
O.H.奥尔森
K.兰贝尔特
P.L.内尔比
L.B.约翰森
M.克雅尔克
H.R.施滕尼克
J.J.福尔贝格
M.范登比格拉尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SANQUIN BLOOD SUPPLY FOUNDATION
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to CN201510070728.6A priority Critical patent/CN104788557A/zh
Publication of CN103209992A publication Critical patent/CN103209992A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2011800549583A 2010-09-15 2011-09-14 具有减少的细胞摄取的因子viii变体 Pending CN103209992A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510070728.6A CN104788557A (zh) 2010-09-15 2011-09-14 具有减少的细胞摄取的因子viii变体

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP10176731 2010-09-15
EP10176731.7 2010-09-15
US38473110P 2010-09-21 2010-09-21
US61/384731 2010-09-21
EP11173768.0 2011-07-13
EP11173768 2011-07-13
US201161507666P 2011-07-14 2011-07-14
US61/507666 2011-07-14
PCT/EP2011/065913 WO2012035050A2 (en) 2010-09-15 2011-09-14 Factor viii variants having a decreased cellular uptake

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510070728.6A Division CN104788557A (zh) 2010-09-15 2011-09-14 具有减少的细胞摄取的因子viii变体

Publications (1)

Publication Number Publication Date
CN103209992A true CN103209992A (zh) 2013-07-17

Family

ID=45832010

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510070728.6A Pending CN104788557A (zh) 2010-09-15 2011-09-14 具有减少的细胞摄取的因子viii变体
CN2011800549583A Pending CN103209992A (zh) 2010-09-15 2011-09-14 具有减少的细胞摄取的因子viii变体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201510070728.6A Pending CN104788557A (zh) 2010-09-15 2011-09-14 具有减少的细胞摄取的因子viii变体

Country Status (7)

Country Link
US (4) US9321827B2 (enExample)
EP (2) EP3466968A1 (enExample)
JP (2) JP6042335B2 (enExample)
CN (2) CN104788557A (enExample)
AU (1) AU2011303916A1 (enExample)
PL (1) PL2616486T3 (enExample)
WO (1) WO2012035050A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011060372A2 (en) * 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii b cell epitope variants having reduced immunogenicity
WO2013083858A1 (en) 2012-04-24 2013-06-13 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
WO2013160005A1 (en) 2012-04-24 2013-10-31 Novo Nordisk A/S Pharmaceutical composition suitable for treatment of haemophilia
CN104661685A (zh) 2012-10-15 2015-05-27 诺和诺德保健Ag（股份有限公司） 因子vii缀合物
MX377401B (es) 2012-12-20 2025-03-07 Basf Agro Bv Composiciones que comprenden un compuesto de triazol.
CN107488154B (zh) 2013-01-09 2021-04-27 巴斯夫农业公司 制备取代环氧乙烷类和三唑类的方法
WO2015003908A1 (en) 2013-07-08 2015-01-15 Basf Se Compositions comprising a triazole compound and a biopesticide
AU2014336252A1 (en) 2013-10-15 2016-04-07 Novo Nordisk Health Care Ag Coagulation factor VII polypeptides
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
BR112016030116B1 (pt) 2014-06-25 2021-07-06 BASF Agro B.V. composições, uso de uma composição, método para o combate dos fungos e material de propagação dos vegetais
EP3617316A4 (en) * 2017-04-27 2020-12-23 Chugai Seiyaku Kabushiki Kaisha COAGULATION FACTOR IX WITH IMPROVED PHARMACOKINETICS
WO2020086686A2 (en) * 2018-10-23 2020-04-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function
CN113692415B (zh) 2019-04-17 2025-01-07 诺和诺德股份有限公司 双特异性抗体
WO2021224369A1 (en) * 2020-05-08 2021-11-11 UCB Biopharma SRL Arrays and methods for identifying binding sites on a protein
CN113248594B (zh) * 2021-04-26 2022-08-30 北京美康基免生物科技有限公司 一种重组凝血因子viii及其应用
WO2025164792A1 (ja) * 2024-02-02 2025-08-07 学校法人自治医科大学 高比活性／高分泌発現型の第ｖｉｉｉ因子改変体、高発現型の第ｖｉｉｉ因子コード核酸及びそれらの用途
WO2025168826A1 (en) 2024-02-08 2025-08-14 Hemab Aps Methods of treating coagulopathy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003047507A2 (en) * 2001-11-30 2003-06-12 Emory University Factor viii c2 domain variants

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2645588A (en) 1987-12-04 1989-06-15 Scripps Clinic And Research Foundation The von willebrand factor binding domain of factor viii
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
AU6029594A (en) * 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP4574007B2 (ja) 1998-04-28 2010-11-04 メルク・セローノ・ソシエテ・アノニム ポリオール−ｉｆｎ−ベータ複体
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
ES2292255T5 (es) 1998-11-10 2017-05-19 Stichting Sanquin Bloedvoorziening Polipéptido del factor 8 con actividad de factor 8:C
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
JP4758608B2 (ja) * 2001-11-07 2011-08-31 ネクター セラピューティックス 分枝ポリマーおよびそれらの結合体
EP1497330B1 (en) 2002-04-29 2010-04-07 Stichting Sanquin Bloedvoorziening Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
JP5570809B2 (ja) 2006-09-01 2014-08-13 ノボ ノルディスク ヘルス ケア アーゲー 修飾タンパク質
CN101778937A (zh) * 2007-06-04 2010-07-14 诺和诺德公司 使用n-乙酰葡糖胺转移酶的o-联糖基化
RU2573587C2 (ru) 2008-02-27 2016-01-20 Ново Нордиск А/С Конъюгированные молекулы фактора viii
WO2011060372A2 (en) 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii b cell epitope variants having reduced immunogenicity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003047507A2 (en) * 2001-11-30 2003-06-12 Emory University Factor viii c2 domain variants

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GARY E. GILBERT ET AL.: "Four Hydrophobic Amino Acids of the Factor VIII C2 Domain Are Constituents of Both the Membrane-binding and von Willebrand Factor-binding Motifs", 《THE JOURNALOF BIOLOGICAL CHEMISTRY》 *
HENRIËT MEEMS ET AL.: "Factor VIII C1 domain residues Lys 2092 and Phe 2093 contribute to membrane binding and cofactor activity", 《BLOOD》 *

Also Published As

Publication number Publication date
WO2012035050A2 (en) 2012-03-22
AU2011303916A1 (en) 2013-03-21
PL2616486T3 (pl) 2019-05-31
WO2012035050A3 (en) 2012-06-14
US20180327479A1 (en) 2018-11-15
JP2013541521A (ja) 2013-11-14
US20160002314A1 (en) 2016-01-07
JP2016180002A (ja) 2016-10-13
US9321827B2 (en) 2016-04-26
EP2616486A2 (en) 2013-07-24
JP6042335B2 (ja) 2016-12-14
US20140057848A1 (en) 2014-02-27
US10047142B2 (en) 2018-08-14
US10906960B2 (en) 2021-02-02
EP2616486B1 (en) 2019-01-02
JP6336522B2 (ja) 2018-06-06
EP3466968A1 (en) 2019-04-10
CN104788557A (zh) 2015-07-22
US20170066813A1 (en) 2017-03-09

Similar Documents

Publication Publication Date Title
US10906960B2 (en) Factor VIII variants having a decreased cellular uptake
CN104411716B (zh) 适用于治疗血友病的化合物
AU2016210689B2 (en) Factor viii compositions and methods of making and using same
US20160207977A1 (en) Compounds Suitable for Treatment of Haemophilia
US20160120954A1 (en) Pharmaceutical Composition Suitable for Treatment of Haemophilia
BR122016022033B1 (pt) conjugados de polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica
CN102971006A (zh) 稳定的因子viii变体
JP2010202664A (ja) 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト
DK2616486T3 (en) FACTOR VIII VARIATIONS WITH DISABLED CELLULAR ADMISSION
AU2013204897A1 (en) Factor VIII variants having a decreased cellular uptake
NZ723509B2 (en) Factor VIII Compositions and Methods of Making and Using Same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: SANQUIN BLOEDVOORZIENING

Effective date: 20140429

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20140429

Address after: Denmark bagsvaerd

Applicant after: Novo Nordisk AS

Applicant after: Sanquin Blood Supply Foundation

Address before: Denmark bagsvaerd

Applicant before: Novo Nordisk AS

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130717